Skip to main content

Table 2 Outcomes of patients at 24 and 48 weeks after starting EVG/COB/TFV/FTC + DRV, stratified by viral load at the start of the regimen

From: Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study

Outcome

24 weeks

48 weeks

Virological response < 50 copies/ml

 Viral load < 50 copies/ml

6/7 (85.7)

4/5 (80.0)

 Viral load ≥ 50 copies/ml

11/26 (42.3)

9/22 (40.9)

Virological response < 200 copies/ml

 Viral load < 50 copies/ml

7/7 (100.0)

5/5 (100.0)

 Viral load ≥ 50 copies/ml

18/26 (69.2)

15/22 (68.2)

CD4 change, cells/microl: median (IQR)

 Viral load < 50 copies/ml

29 (14–48)

8 (− 85–50)

 Viral load ≥ 50 copies/ml

− 6 (− 134–107)

− 16 (− 116–77)

Patients stopping the regimen for any reason

 Viral load < 50 copies/ml

0/10 (0)

2/10 (20.0)

 Viral load ≥ 50 copies/ml

8/29 (27.6)

13/29 (44.8)

Patients stopping the regimen due to treatment failure

 Viral load < 50 copies/ml

0/10 (0)

0/10 (0)

 Viral load ≥ 50 copies/ml

4/29 (13.8)

4/29 (13.8)

Patients stopping the regimen due to toxicity

 Viral load < 50 copies/ml

0/10 (0)

0/10 (0)

 Viral load ≥ 50 copies/ml

0/29 (0)

0/29 (0)

  1. Values are expressed as n/total (%) unless stated otherwise
  2. IQR Interquartile range